News
BridgeBio acquires the shares of Eidos Therapeutics.
BridgeBio Pharma, Inc. a company focused on genetic diseases, and Eidos Therapeutics, Inc. a company focused on transthyretin (TTR) amyloidosis (ATTR), announced they have entered into a definitive agreement under which BridgeBio has agreed to acquire all of the outstanding common stock of Eidos it does not already own, representing approximately 36.3% of Eidos’ outstanding shares. Eidos stockholders will have the right to receive in the transaction, at their election, either 1.85 shares of BridgeBio common stock or $73.26 in cash per Eidos share in the transaction, up to an aggregate maximum of $175 million of cash. The agreement was unanimously approved by BridgeBio’s Board of Directors and was approved by Eidos’ Board of Directors based upon the unanimous recommendation of a special committee of independent directors of Eidos.
Type: industry